Skip to content
Business Segments · Intangible asset impairment charge

Business Segments — Intangible asset impairment charge

Year-over-year, this metric declined by 100.0%, from $379M to $0. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ1 2026May 5, 2026

How to read this metric

An increase signals that previous investments or acquisitions are underperforming or have lost commercial viability.

Detailed definition

Non-cash charges recognized when the carrying value of an intangible asset, such as acquired intellectual property or li...

Peer comparison

Commonly reported by peers as 'Impairment of Intangible Assets'.

Metric ID: vrtx_segment_pharmaceuticals_intangible_asset_impairment_charge

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$0$0$0$0$0$379M$0$0$0$0
QoQ Change-100.0%
YoY Change-100.0%
Range$0$379M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%

Frequently Asked Questions

What is Vertex Pharmaceuticals's business segments — intangible asset impairment charge?
Vertex Pharmaceuticals (VRTX) reported business segments — intangible asset impairment charge of $0 in Q1 2026.
How has Vertex Pharmaceuticals's business segments — intangible asset impairment charge changed year-over-year?
Vertex Pharmaceuticals's business segments — intangible asset impairment charge decreased by 100.0% year-over-year, from $379M to $0.
What does business segments — intangible asset impairment charge mean?
A write-down in the value of intangible assets like patents or acquired drug rights.